藥 物 回 收
|
| |
| The United States: Eli Lilly and Company issues voluntary nationwide recall of one lot of Glucagon Emergency Kit due to loss of potency (English only) |
| |
The US Food and Drug Administration (FDA) announces that Eli Lilly and Company is voluntarily recalling lot D239382D of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 ml syringe) to the consumer/user level. Lilly is recalling lot D239382D to the patient level because of a product complaint reporting that the vial of Glucagon was in liquid form instead of the powder form. The firm’s investigation indicates that the liquid in this Glucagon vial could be related to the manufacturing process. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.
Severe hypoglycemia in patients with diabetes, if not reversed, can potentially cause adverse health consequences ranging from transient, minor complaints to neurological damage, seizures, and even death if not promptly treated. Associated with the one product complaint, it was reported to Lilly that the involved patient experienced lack of drug effect and also reported subsequent seizures.
Please refer to the following website in FDA for details:
http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/eli-lilly-and-company-issues-voluntary-nationwide-recall-one-lot-glucagonr-emergency-kit-due-loss
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/Monday, Sep 27, 2021
Issued at HKT 15:00
|
| |
|
